Information Provided By:
Fly News Breaks for July 2, 2019
IOVA
Jul 2, 2019 | 09:13 EDT
Piper Jaffray analyst Joseph Catanzaro says guidance from the FDA, as announced this morning by the company, puts Iovance Biotherapeutics on track for a Biologics License Application in cervical cancer in the second half of 2020. This is a positive outcome and largely in-line with where consensus has moved following the ASCO presentation, Catanzaro tells investors in a research note. He maintains an Overweight rating on Iovance Biotherapeutics with a $30 price target.
News For IOVA From the Last 2 Days
There are no results for your query IOVA